Redeye comments on Oncopeptides’ 3rd quarter report. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m. Although sales were below our forecast in Q3, we have expectations for higher growth in the coming quarters.
LÄS MER